Novo Nordisk Faces Shareholder Lawsuit Over CagriSema Trial Protocols
A New Jersey federal court judge ruled that Novo Nordisk must face part of a shareholder lawsuit alleging the company engaged in fraudulent practices by altering protocols for its key trial involving the experimental drug CagriSema. The plaintiffs claim these changes misled investors about the drug's potential and market readiness. The case centers on allegations that Novo Nordisk manipulated clinical trial data to present an overly optimistic view of CagriSema, which is being developed as a treatment for type 2 diabetes. If proven true, such actions could have significant implications for investor trust and regulatory scrutiny. This legal development comes at a critical time for the company's stock performance and reputation in the pharmaceutical sector.
Tickers: $NVO